Webinar

Why Deep Tech Is Eating Venture Capital

Matt Caspari FFDT

Discover the transformative power of Deep Tech with our exclusive webinar, “Why Deep Tech Is Eating Venture Capital,” hosted by Matt Caspari, Managing Partner of Alumni Ventures Deep Tech Fund, alongside Carl Choi from the Deep Tech Fund.

See video policy below.

Join us as we delve into the burgeoning landscape where science and engineering converge to tackle the most complex challenges and reshape industries. Watch now to gain invaluable insights into the future of venture capital and how Deep Tech is driving unprecedented innovation and returns.

In this one-of-a-kind webinar, you will learn:

  • Home

    Explore the immense potential of Deep Tech startups to disrupt industries and reshape entire sectors.
  • Home

    Learn about the exponential growth of Deep Tech investments, backed by compelling data and analysis.
  • Home

    Gain strategic knowledge on navigating the evolving venture capital landscape and seizing opportunities in Deep Tech.
Alumni Ventures is America’s largest venture capital firm for individual investors.
About Alumni Ventures

Note: You must be accredited to invest in venture capital. Important disclosure information can be found at av-funds.com/disclosures

About your presenter

Matt Caspari
Matt Caspari

Managing Partner, Deep Tech Fund

Matt Caspari is a Managing Partner at Alumni Ventures, where he leads the Deep Tech, Georgetown (Potomac Ventures) and UC Berkeley (Strawberry Creek Ventures) funds. He invests in mission-driven founders developing groundbreaking technologies. His investments encompass a diverse range of sectors, including AI, agriculture, aviation, battery technology, cybersecurity, direct air capture of CO2, energy generation, longevity, and robotics. Prior to Alumni Ventures, Matt gained operational experience as a two-time venture-backed founder/CEO and as a leader of the innovation team at Nike. He was the founding CEO of Aurora Biofuels, a deep tech venture that grew to 100+ employees, secured over $100 million in funding and was acquired by Reliance Industries. In earlier roles, Matt served as a strategic management consultant at Cambridge Pharma Consultancy, later acquired by IMS Health, and gained experience on the M&A team at Bloomberg. He holds a BS in Biochemistry from Georgetown University and an MBA with a Certificate in Entrepreneurship from UC Berkeley.

Webinar Registration